Press release from Companies
Published: 2026-04-08 14:32:22
Spermosens AB ("Spermosens" or the "Company") announces that development of the JUNO-Checked Generation 3 system is now complete. This innovative sensor system meets the performance standards necessary for a commercially viable product. The Company is preparing to initiate patient recruitment for a clinical validation study at the Reproductive Medicine Center (RMC) in Malmö. This represents a major milestone in the strategic plan to bring improved fertility diagnostics to the market through commercial partnerships.
Significant improvements of JUNO-Checked Generation 3
The development of JUNO-Checked Generation 3 has focused on the specific needs of clinics and laboratories. This system features significant key technical improvements, such as significantly shorter analysis times and a more robust sensor design to support high-volume clinical workflows. These enhancements are intended to reduce technical and operational risks for future partners and support integration into existing laboratory environment. The system is designed for compatibility with established laboratory platforms, enabling seamless adoption in clinical practice.
Clinical validation and go to market
The clinical validation study will be conducted at Reproductive Medicine Center (RMC) in Malmö and is designed to validate the performance of the new system in a clinical environment. Patient recruitment is expected to begin shortly. The study focuses on couples undergoing standard IVF due to unexplained infertility, where semen samples are classified as normal in routine testing. The aim is to demonstrate that JUNO-Checked provides additional diagnostic value by identifying sperm-related dysfunctions not detected by conventional methods.
Completion of the study is expected by the end of the year. Successful validation is a key step toward registration and commercialization. In line with the Company strategy, Spermosens aims to bring JUNO-Checked to the market through license or co-development agreements. This approach is designed to reduce capital needs and improve the likelihood of a successful market introduction through established companies. JUNO-Checked addresses a global fertility market where improved functional testing is essential to support clinical decisions and improve treatment outcomes for millions of couples.
Dr. Tore Duvold, CEO of Spermosens, comments: " I am pleased with the progress we have made and the improvements achieved with Generation 3. The system has been developed to meet the needs of clinics and laboratories and strengthen our position in discussions with potential partners. Initiating the clinical validation study is an important next step in demonstrating the value of our technology. I would like to thank the Reproductive Medicine Center in Malmö for their continued support."
For more information, please contact:
Tore Duvold, CEO
About Spermosens AB Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company''s shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com.
